Adjuvant radiotherapy in the management of porocarcinoma with lymphatic micrometastasis

Basit Öğe Kaydı
dc.authoridGokoz, Ozay/0000-0001-9537-1127
dc.authoridGokoz, Ozay/0000-0001-9537-1127
dc.authoridKahvecioglu, Alper/0000-0001-8714-2383
dc.authorwosidGokoz, Ozay/AAC-7739-2021
dc.authorwosidGokoz, Ozay/I-9743-2013
dc.contributor.authorKahvecioglu, Alper
dc.contributor.authorElcin, Gonca
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorGokoz, Ozay
dc.contributor.authorYazici, Gozde
dc.date.accessioned2024-05-19T14:46:16Z
dc.date.available2024-05-19T14:46:16Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBackground. Porocarcinoma is a rare skin tumor originating from dermal sweat glands. Surgical procedures are the first choice of treatment, but the role of adjuvant therapies, such as chemotherapy and radiotherapy (RT), is not clear. In this case report and review of the literature, we aimed to present a patient who underwent adjuvant RT for the diagnosis of porocarcinoma with lymphatic micrometastasis and a review of the current literature. Case summary. A 61-year-old male was admitted to the dermatology department for a nodular lesion on the left knee skin. An excisional biopsy was performed, and the pathology result was reported as porocarcinoma. The closest surgical margin of the tumor was 0.2 cm. In the inguinal sentinel lymph node sampling, two of the three removed lymph nodes had micrometastases. Then, adjuvant RT was applied to the left inguinofemoral lymphat- ics and primary tumor bed. No recurrence was observed in the patient with a follow-up period of 24 months. No acute or late toxicity was observed including lymphedema, subcutaneous fibrosis, or stiffness of the knee joint. Conclusions. Although adjuvant RT is not a routinely recommended treatment, it can be applied to increase lo- cal and regional control in patients with high-risk factors for recurrence or with lymph node metastases. There is a great need for clinical studies clarifying the role of RT, but for now, all patients should undergo multidisciplinary evaluation when a decision on adjuvant therapies is made.en_US
dc.identifier.doi10.5603/OCP.2023.0003
dc.identifier.endpage128en_US
dc.identifier.issn2450-1654
dc.identifier.issn2450-6478
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85164695799en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage124en_US
dc.identifier.urihttps://doi.org10.5603/OCP.2023.0003
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5482
dc.identifier.volume19en_US
dc.identifier.wosWOS:000988487000001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherVia Medicaen_US
dc.relation.ispartofOncology In Clinical Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectPorocarcinomaen_US
dc.subjectRadiotherapyen_US
dc.subjectSkin Canceren_US
dc.titleAdjuvant radiotherapy in the management of porocarcinoma with lymphatic micrometastasisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu